Improved treatment of paget's disease with dimethylaminohydroxypropylidene bisphosphonate
Authors:
- 1 February 1993
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 8 (2) , 175-182
Abstract
A group of 89 patients with Paget's disease of bone were treated with different intravenous or oral doses of the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate (dimethyl-APD). Biochemical remission was obtained in 82% of treatments, and in the rest a clear response was found. Oral dimethyl-APD was well tolerated, and a dose of 200 mg/day for 10 days was sufficient to induce remission in the majority of patients. The remission probability was 3 months for 50% of patients, and the recurrence-free period was 27 months. The remission probability as well as the recurrence-free period did not differ among oral and intravenous treatments or among patients who had never been treated with nitrogen-containing bisphosphonates and those who had received pamidronate in the past and were treated for a recurrence of the disease. Dimethyl-APD is a very effective bisphosphonate devoid of side effects, which given for a short period can induce long-lasting remissions in patients with Paget's disease of bone.Keywords
Funding Information
- Dutch Organization (NWO 900-541-191)
This publication has 18 references indexed in Scilit:
- Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonateJournal of Bone and Mineral Research, 1990
- Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonateJournal of Bone and Mineral Research, 1989
- Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated boneBone and Mineral, 1989
- Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).BMJ, 1987
- INTRAVENOUS CLODRONATE IN THE TREATMENT AND RETREATMENT OF PAGET'S DISEASE OF BONEThe Lancet, 1985
- FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASEThe Lancet, 1984
- Effects of ethane-1 hydroxy-1, 1-Diphosphonate (5 mg/kg/day dose) onquantitative bone histology in paget's disease of boneMetabolic Bone Disease and Related Research, 1981
- TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- DIPHOSPHONATES AND PAGET'S DISEASE OF BONEThe Lancet, 1971
- EFFECTS OF CALCITONIN ON PATIENTS WITH PAGET'S DISEASE, THYROTOXICOSIS, OR HYPERCALCÆMIAThe Lancet, 1968